Clinical Trial Update: APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating APR-246 in combination with venetoclax and azacitidine for TP53-mutant myeloid malignancies has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• APR-246 (eprenetapopt)
• VIDAZA (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: Aprea Therapeutics | Conditions: Myeloid Malignancy | Phase 1 | Status: COMPLETED | Results posted: 2025-02-21